Zurko Research is a clinical evaluation and in vitro testing center. We evaluate the safety and efficacy of cosmetic and cosmeceutical products, as well as medical devices. | Zurko Research is a leading Contract Research Organization (Third Party Testing House) established in 2005. We offer a wide range of Clinical Safety & Efficacy studies for Cosmetics, OTCs and Nutritional Supplement and conduct more than 8,000 studies every year across our 3 testing sites. Our wide range of studies and rapid turnaround time, combined with rigorous quality standards, makes us a partner of choice for the Personal Care Industry.
XenTech
XenTech is a 20 years old CRO specialized in the preclinical evaluation of anti-cancer agents with an in vitro and an in vivo human tumor-based platform for accurate and highly predictive testing/profiling of many anti-cancer therapy modalities: small molecules, drug-conjugates, immuno-therapeutics,… As the selection of relevant models is crucial to test candidates based on their target and mechanism of action, XenTech provides all the required resources for the confident identification of these models. The panel of 250+ deeply characterized Patient Derived Xenograft (PDX) models closely replicates the biological features of human tumors and covers the molecular diversity of clinical diseases for breast, prostate, bladder, lung, ovarian cancers and many other indications. All our studies are governed by a high-standard system of quality management and provide robust data for confident progression to clinical phases.
Xellar Biosystems
Xellar Biosystems is a Wet Artificial Intelligence (AI) biotechnology company, combining machine learning and AI with large-scale wet-lab experiments, tackling the most challenging problem in modern drug discovery – harnessing the complexity of human biology to accelerate drug discovery and development.
X-Chem, Inc.
X-Chem is redefining small molecule drug discovery through a powerful combination of computational sciences, discovery chemistry and data-driven insight. As the pioneer and global leader in DNA-encoded library (DEL) technology, X-Chem provides the foundation for smarter hit identification, accelerated lead progression and greater confidence in early discovery. X-Chem partners globally to turn complex discovery challenges into actionable solutions.
WuXi XDC
WuXi XDC （ 2268.HK ） is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC is a subsidiary of WuXi Biologics
WuXi AppTec
WuXi AppTec offers a comprehensive platform of targeted oncology models and translational services to support cancer drug development teams within the global pharmaceutical and healthcare industry. Our services include CAR-T cell therapy, antibody-drug conjugates, CRISPR-mediated target validation, drug-resistant CDX/PDX tumor models, and discovery/clinical biomarker services. | As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
Wuhan Healthgen Biotechnology Corp.
Wuhan Healthgen Biotechnology Corp. (Stock Code: 668765) is a molecular pharmaceutical company specializing in the development, manufacturing, and marketing of recombinant proteins. Using its proprietary OryzHiExp platform, Healthgen achieves high-yield expression of proteins and peptides in rice grains. Its flagship product, Recombinant Human Serum Albumin (OsrHSA), is a critical reagent used in cell culture, medical devices, biopharmaceutical excipients, and cosmetic additives.
Worldwide Clinical Trials
About Worldwide Clinical Trials Worldwide Clinical Trials (Worldwide) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,400 professionals operating across more than 70 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase – from early-stage and first-in-human studies through Phase III registration trials. The company’s flexible service model – spanning full-service trial management to functional service partnerships through Worldwide Flex – is powered by a people-first, partnership-driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision-making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research. Learn more at www.worldwide.com
Women of Color Breast Cancer Survivors Support Project
WOC is an advocacy group of breast cancer survivors, supporters, and families championing racial and economic justice in breast cancer diagnosis, treatment, and prevention for BIPOC women, while working to eliminate systemic barriers to health equity.
Wasatch BioLabs
Wasatch BioLabs (WBL) is an independent biotechnology company with a disruptive approach to research and diagnostics. We are an R&D and Oxford Nanopore Technologies-certified laboratory that offers DNA and RNA sequencing services to researchers and clinical service providers. WBL’s solutions span both standard Oxford Nanopore Technologies sequencing services as well as proprietary methylation sequencing services built off of WBL’s NESSI-Seq platform, that expand the capabilities of the nanopore platform. | Wasatch BioLabs, a leading NGS sequencing service provider, harnesses advanced native-read sequencing and streamlined R&D workflows—translating breakthrough discovery into real-world outcomes.